Teleflex’s Freesolve™ RMS Receives FDA Breakthrough Device Designation
The U.S. Food and Drug Administration has granted Breakthrough Device Designation to Teleflex Incorporated’s Freesolve™ Resorbable Magnesium Scaffold for percutaneous coronary intervention. This designation recognizes technologies addressing unmet clinical needs for life-threatening conditions. Teleflex is currently conducting the BIOMAG™-III Pivotal Trial to support a future U.S. FDA Premarket Approval application. Together, the designation and ongoing clinical evaluation may accelerate the future commercial availability of the Freesolve™ RMS device in the United States market, enhancing the company’s cardiovascular product portfolio and strategic positioning in advanced coronary interventions.
Teleflex Incorporated (NYSE: TFX) announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation to the company’s Freesolve™ Resorbable Magnesium Scaffold for percutaneous coronary intervention, or PCI.
Freesolve™ Resorbable Magnesium Scaffold is also referred to as Freesolve™ RMS. To qualify for Breakthrough Device Designation, a device technology must address an unmet clinical need and show the potential to provide more effective treatment for life-threatening or irreversibly debilitating diseases or conditions.
Teleflex is also conducting the BIOMAG™-III Pivotal Trial (NCT07258290), which is designed to support a future U.S. FDA Premarket Approval application. Together with the ongoing trial, the designation may support the future commercial availability of Freesolve™ RMS in the United States.
This article may include AI-generated content that is human-reviewed, which is for reference and general information purposes only and does not constitute investment advice.
Recommended Articles










Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.